Hruz Paul W
Department of Pediatrics, Department of Cell Biology and Physiology Washington, University School of Medicine, St. Louis, MO 63110.
Am J Infect Dis. 2006;2(3):187-192. doi: 10.3844/ajidsp.2006.187.192.
A complete understanding of the molecular mechanisms leading to HIV-associated insulin resistance remains elusive. Complex interrelationships between genetic predisposition, disease-related body changes and multidrug therapy all contribute to alterations in glucose homeostasis. These abnormalities can be differentiated between acute and reversible changes directly induced by HAART medications and more chronic and less reversible changes due to the development of lipodystrophy and hyperlipidemia. Implicated pathways include changes in adipokine secretion, insulin signaling, lipid homeostasis and disease-related increases in inflammatory mediators. The insulin responsive facilitative glucose transporter GLUT4 is the first molecule to have been identified as a direct target of HIV protease inhibitors. Efforts to elucidate the mechanisms directly responsible for the evolution of insulin resistance during HIV infection and therapy will be greatly assisted by the further identification and characterization of direct molecular targets amenable to pharmacologic therapy and/or the development of newer antiretroviral agents that do not adversely affect these target proteins.
对导致HIV相关胰岛素抵抗的分子机制的全面理解仍然难以捉摸。遗传易感性、疾病相关的身体变化和多药治疗之间复杂的相互关系都导致了葡萄糖稳态的改变。这些异常可分为由高效抗逆转录病毒治疗(HAART)药物直接引起的急性和可逆性变化,以及由于脂肪代谢障碍和高脂血症发展导致的更慢性和较不可逆的变化。涉及的途径包括脂肪因子分泌、胰岛素信号传导、脂质稳态的变化以及疾病相关的炎症介质增加。胰岛素反应性易化葡萄糖转运体GLUT4是第一个被确定为HIV蛋白酶抑制剂直接靶点的分子。进一步鉴定和表征适合药物治疗的直接分子靶点,和/或开发对这些靶蛋白无不利影响的新型抗逆转录病毒药物,将极大地有助于阐明HIV感染和治疗期间直接导致胰岛素抵抗演变的机制。